)
Visual21 Nov 2025
Data center suppliers
Ventyx Biosciences (VTYX) investor relations material
Ventyx Biosciences Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary19 Nov, 2025
Company overview and strategic focus
Expanded from immunology to neuro, cardiovascular, and metabolic areas since 2021.
Shifted focus to NLRP3 inflammasome after earlier compounds were not competitive in Crohn's and psoriasis.
Built a portfolio of peripheral and CNS-penetrant NLRP3 inhibitors, aiming for best-in-class status.
Differentiation based on engineered brain-biased molecules and lack of toxicity signals in studies.
Positioned as a leader in a field with increasing competition and interest from major pharma.
Clinical development and trial insights
Lead CNS-penetrant compound 3232 showed strong biomarker changes but no effect on weight loss in obesity trial.
Demonstrated significant reduction in inflammation markers (hsCRP, IL-6, fibrinogen, SAA) and direct effects on Lp(a).
No observed link between neuroinflammation and feeding behavior in humans, unlike in mice.
Peripheral compound 2735 is in a phase II trial for recurrent pericarditis (RP), with interim data expected from 10+ patients.
Success in RP defined by pain score reduction to 0-1 and CRP reduction, aiming to match injectable competitor efficacy.
Forward-looking statements and partnerships
Strategic interest in neurodegenerative and cardiovascular indications, with Sanofi holding ROFN on 3232.
Next update tied to data package from the obesity trial; negotiation and signing period to follow.
Phase III planning for 2735 in RP expected to begin in the second half of the year, with protocol changes to include QD dosing.
Safety profile for both lead compounds remains strong, with no significant signals in trials to date.
Broader industry excitement and collaboration in the inflammasome space, with room for multiple drugs.
What's the 3232 partnering strategy for neurodegeneration?
How will 2735's oral profile compete with Arkalyst?
What are the broader implications of the Sanofi Rofan?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ventyx Biosciences earnings date
Q4 202526 Feb, 2026
Next Ventyx Biosciences earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel oral therapies designed to treat patients with autoimmune and inflammatory disorders. The company's approach involves selectively modulating key immune targets to create differentiated medicines. Ventyx Biosciences is working on several promising drug candidates, including a selective allosteric tyrosine kinase type 2 inhibitor and a sphingosine 1 phosphate receptor modulator, which are in various stages of clinical trials targeting conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Additionally, they are developing inhibitors targeting the NLRP3 inflammasome. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage